The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma

Paola Paglia, Ivano Arioli, Nicole Frahm, Trinad Chakraborty, Mario P. Colombo, Carlos A. Guzmàn

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Listeria monocytogenes has been proposed as a carrier to elicit major histocompatibility complex class-I restricted immune responses able to protect against tumor challenge. In this study the properties of the attenuated L. monocytogenes Δmpl2 mutant has been evaluated in vivo against a highly aggressive mouse fibrosarcoma which expresses β-galactosidase (β-gal) as a tumor-associated antigen (TAA). Immunization with the vaccine prototypes resulted in both elicitation of specific antibodies and generation of cytotoxic lymphocytes (CTL). Oral vaccination protected 55-64% of the immunized animals from tumor take (p <0.01) and strongly reduced the average size of the tumor in the other 34-45% (p <0.01). Vaccinated mice developed a long-lasting response, which resulted in 100% protection from a subsequent tumor challenge. Substitution of the whole TAA by its CTL-defined immunodominant epitope resulted in 43% protection, suggesting a contribution of the humoral response to the observed antitumor effect. No statistically significant differences were observed in the antitumor response when mice were immunized with strains expressing the immunodominant TAA epitope in the context of carrier proteins which were either exported or restricted to the bacterial cytoplasm. This suggests that the topology of the recombinant antigen does not play a major role in the outcome of the protective response.

Original languageEnglish
Pages (from-to)1570-1575
Number of pages6
JournalEuropean Journal of Immunology
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 1997

Fingerprint

Fibrosarcoma
Listeria monocytogenes
Neoplasm Antigens
Vaccines
Immunodominant Epitopes
Neoplasms
Galactosidases
Lymphocytes
Major Histocompatibility Complex
Epitopes
Immunization
Carrier Proteins
Cytoplasm
Vaccination
Antigens
Antibodies

Keywords

  • Antitumor immune response
  • Listeria monocytogenes
  • Oral vaccine

ASJC Scopus subject areas

  • Immunology

Cite this

The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. / Paglia, Paola; Arioli, Ivano; Frahm, Nicole; Chakraborty, Trinad; Colombo, Mario P.; Guzmàn, Carlos A.

In: European Journal of Immunology, Vol. 27, No. 6, 06.1997, p. 1570-1575.

Research output: Contribution to journalArticle

@article{2781b90b9ebb4a3e88a9041f472854e9,
title = "The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma",
abstract = "Listeria monocytogenes has been proposed as a carrier to elicit major histocompatibility complex class-I restricted immune responses able to protect against tumor challenge. In this study the properties of the attenuated L. monocytogenes Δmpl2 mutant has been evaluated in vivo against a highly aggressive mouse fibrosarcoma which expresses β-galactosidase (β-gal) as a tumor-associated antigen (TAA). Immunization with the vaccine prototypes resulted in both elicitation of specific antibodies and generation of cytotoxic lymphocytes (CTL). Oral vaccination protected 55-64{\%} of the immunized animals from tumor take (p <0.01) and strongly reduced the average size of the tumor in the other 34-45{\%} (p <0.01). Vaccinated mice developed a long-lasting response, which resulted in 100{\%} protection from a subsequent tumor challenge. Substitution of the whole TAA by its CTL-defined immunodominant epitope resulted in 43{\%} protection, suggesting a contribution of the humoral response to the observed antitumor effect. No statistically significant differences were observed in the antitumor response when mice were immunized with strains expressing the immunodominant TAA epitope in the context of carrier proteins which were either exported or restricted to the bacterial cytoplasm. This suggests that the topology of the recombinant antigen does not play a major role in the outcome of the protective response.",
keywords = "Antitumor immune response, Listeria monocytogenes, Oral vaccine",
author = "Paola Paglia and Ivano Arioli and Nicole Frahm and Trinad Chakraborty and Colombo, {Mario P.} and Guzm{\`a}n, {Carlos A.}",
year = "1997",
month = "6",
doi = "10.1002/eji.1830270637",
language = "English",
volume = "27",
pages = "1570--1575",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "6",

}

TY - JOUR

T1 - The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma

AU - Paglia, Paola

AU - Arioli, Ivano

AU - Frahm, Nicole

AU - Chakraborty, Trinad

AU - Colombo, Mario P.

AU - Guzmàn, Carlos A.

PY - 1997/6

Y1 - 1997/6

N2 - Listeria monocytogenes has been proposed as a carrier to elicit major histocompatibility complex class-I restricted immune responses able to protect against tumor challenge. In this study the properties of the attenuated L. monocytogenes Δmpl2 mutant has been evaluated in vivo against a highly aggressive mouse fibrosarcoma which expresses β-galactosidase (β-gal) as a tumor-associated antigen (TAA). Immunization with the vaccine prototypes resulted in both elicitation of specific antibodies and generation of cytotoxic lymphocytes (CTL). Oral vaccination protected 55-64% of the immunized animals from tumor take (p <0.01) and strongly reduced the average size of the tumor in the other 34-45% (p <0.01). Vaccinated mice developed a long-lasting response, which resulted in 100% protection from a subsequent tumor challenge. Substitution of the whole TAA by its CTL-defined immunodominant epitope resulted in 43% protection, suggesting a contribution of the humoral response to the observed antitumor effect. No statistically significant differences were observed in the antitumor response when mice were immunized with strains expressing the immunodominant TAA epitope in the context of carrier proteins which were either exported or restricted to the bacterial cytoplasm. This suggests that the topology of the recombinant antigen does not play a major role in the outcome of the protective response.

AB - Listeria monocytogenes has been proposed as a carrier to elicit major histocompatibility complex class-I restricted immune responses able to protect against tumor challenge. In this study the properties of the attenuated L. monocytogenes Δmpl2 mutant has been evaluated in vivo against a highly aggressive mouse fibrosarcoma which expresses β-galactosidase (β-gal) as a tumor-associated antigen (TAA). Immunization with the vaccine prototypes resulted in both elicitation of specific antibodies and generation of cytotoxic lymphocytes (CTL). Oral vaccination protected 55-64% of the immunized animals from tumor take (p <0.01) and strongly reduced the average size of the tumor in the other 34-45% (p <0.01). Vaccinated mice developed a long-lasting response, which resulted in 100% protection from a subsequent tumor challenge. Substitution of the whole TAA by its CTL-defined immunodominant epitope resulted in 43% protection, suggesting a contribution of the humoral response to the observed antitumor effect. No statistically significant differences were observed in the antitumor response when mice were immunized with strains expressing the immunodominant TAA epitope in the context of carrier proteins which were either exported or restricted to the bacterial cytoplasm. This suggests that the topology of the recombinant antigen does not play a major role in the outcome of the protective response.

KW - Antitumor immune response

KW - Listeria monocytogenes

KW - Oral vaccine

UR - http://www.scopus.com/inward/record.url?scp=0030969822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030969822&partnerID=8YFLogxK

U2 - 10.1002/eji.1830270637

DO - 10.1002/eji.1830270637

M3 - Article

VL - 27

SP - 1570

EP - 1575

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 6

ER -